Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.96 USD | -2.63% | +6.86% | -6.92% |
Mar. 07 | Lumos Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 07 | Transcript : Lumos Pharma, Inc., 2023 Earnings Call, Mar 07, 2024 |
Financials (USD)
Sales 2024 * | 8.81M | Sales 2025 * | 8.64M | Capitalization | 24.02M |
---|---|---|---|---|---|
Net income 2024 * | -35M | Net income 2025 * | -39M | EV / Sales 2024 * | 2.73 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.78 x |
P/E ratio 2024 * |
-1.05
x | P/E ratio 2025 * |
-1.48
x | Employees | 33 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 64.98% |
Latest transcript on Lumos Pharma, Inc.
1 day | -2.63% | ||
1 week | +6.86% | ||
Current month | +5.34% | ||
1 month | +7.25% | ||
3 months | -1.00% | ||
6 months | -15.19% | ||
Current year | -6.92% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Hawkins
CEO | Chief Executive Officer | 75 | 10-08-31 |
Lori Lawley
DFI | Director of Finance/CFO | 40 | 20-02-29 |
John McKew
PSD | President | 59 | 15-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lota Zoth
BRD | Director/Board Member | 64 | 12-10-31 |
Richard Hawkins
CEO | Chief Executive Officer | 75 | 10-08-31 |
Kevin Lalande
BRD | Director/Board Member | 51 | 13-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 2.96 | -2.63% | 69,636 |
24-05-02 | 3.04 | +0.66% | 128,322 |
24-05-01 | 3.02 | +7.47% | 278,322 |
24-04-30 | 2.81 | -0.71% | 19,747 |
24-04-29 | 2.83 | +2.17% | 13,699 |
Delayed Quote Nasdaq, May 03, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.92% | 24.02M | |
+25.69% | 47.86B | |
+46.90% | 41.42B | |
-3.46% | 40.66B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- LUMO Stock